Vir Biotechnology (VIR) EBITDA (2018 - 2026)

Vir Biotechnology has reported EBITDA for 9 years, with the latest figure at -$132.3 million in Q1 2026.

• Quarterly EBITDA rose 5.2% year-over-year to -$132.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$472.1 million (up 27.0% YoY) and the FY2025 annual result came in at -$479.3 million, up 18.37% from the prior year.
• EBITDA retreated to -$132.3 million in Q1 2026 per VIR's latest filing, from -$47.9 million in the prior quarter.
• Over five years, EBITDA peaked at $1.0 billion in Q1 2022 and troughed at -$231.3 million in Q3 2024.
• A 5-year average of -$61.8 million and a median of -$139.5 million in 2025 frame the typical range for EBITDA.
• The widest YoY moves for EBITDA: up 739.1% in 2022, down 469.11% in 2022.
• Over 5 years, EBITDA stood at -$150.5 million in 2022, then advanced by 7.63% to -$139.0 million in 2023, then rose by 15.73% to -$117.2 million in 2024, then surged by 59.09% to -$47.9 million in 2025, then sank by 176.06% to -$132.3 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$132.3 million, -$47.9 million, and -$173.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.